NCT06187727View on ClinicalTrials.gov

Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

PHASE4RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions

Myocardial InfarctionHeart Failure

Interventions

DRUG

Henagliflozin

After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.

Trial Locations (1)

100853

RECRUITING

Chinese PLA general hospital, Beijing

All Listed Sponsors

lead

Qian geng

OTHER